Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactoferrin in Hepatic Encephalopathy
NCT06072521Phase 2Unknown
- Sponsor
- Al-Azhar University
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bovine lactoferrin in hepatic encephalopathy (HE) (3 arms), sponsored by Al-Azhar University. Primary endpoints: Change in serum concentration of inflammatory cytokines at 15 days, Change in serum concentration of Nuclear factor kB at 15 days and 1 more. Status: unknown.
02
Drugs
bovine lactoferrin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT06072521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072521.